21 May, 2026

International expansion of food supplements: the mistake of notifying without strategy

NutraIngredients published an analysis by África Gallego, director and senior regulatory consultant at LegaleGo Regulatory, about one of the most common mistakes we continue to see in the international expansion of food supplements: assuming that a product validated in one country is automatically ready for the entire European market.

And this is precisely where many regulatory problems begin.

Because in international expansion of food supplements, risk rarely appears at the beginning.

The product is formulated.
The label is adapted.
The notification is submitted.
The product enters the market.

And everything seems compliant.

Until the real regulatory differences between countries begin to appear: national interpretations, administrative practice, inspections or post-market requests.

At that point, the problem stops being technical.

And becomes a business problem.

International expansion of food supplements does not end with notification

One of the most common mistakes in international expansion of food supplements is treating regulatory review as the final step of the process.

When the formula is already closed.
When the brand has already been registered.
When the packaging has already been produced.
When the commercial launch has already been planned.

At that stage, many strategic decisions are already difficult — or even impossible — to change.

And this is where real regulatory risk begins.

Because the problem is not always whether a product can be notified.

Very often, the problem appears later:

• when an ingredient receives a different interpretation in another market;
• when an authority questions the product category;
• when claims or warnings are challenged;
• or when a marketplace blocks the product in a specific country.

This is why, in food supplements, notification does not mean validation.

The “European formulation” often does not exist

One of the most dangerous assumptions in international expansion is believing that a single formulation can work across the entire European Union.

In practice, this rarely happens.

The analysis published in NutraIngredients explained how the same product may receive completely different treatment depending on the country.

And this is not theoretical.

We see it constantly in European administrative practice.

For example:

• ingredients accepted in one market and challenged in another;
• different maximum levels for vitamins and minerals;
• different interpretations regarding botanicals;
• or products changing category depending on the country.

Melatonin is one of the most common examples.

Depending on the country and the dosage used, the same product may be considered either a food supplement or a medicinal product.

And that difference completely changes the regulatory scenario.

As we already explained in our previous analysis on replicating regulatory decisions across Europe, the problem is often not the European legislation itself, but how each country interprets and applies that framework in practice.

The real problems appear when the product is already on the market

This is where many companies discover the real cost of poorly planned international expansion.

Because when problems appear, the product already has:

• distributed stock;
• active marketplaces;
• SEO positioning;
• distributors;
• launched campaigns;
• and significant investment behind it.

In our strategic Vitafoods dossier, we used a very clear example: a Garcinia cambogia product initially accepted in Italy that later could not be commercialised in France.

The consequences?

• four-month launch delay;
• mandatory reformulation;
• loss of customers in the French market.

And this happens more often than many companies imagine.

Because the problem does not appear when the product is notified.

It appears months later, when the entire commercial structure is already built.

Regulatory review and regulatory risk in multi-country expansion

This is probably the most important point.

Regulation should not be used as a final validation of a finished product.

It should be part of the strategic decision-making process from the beginning.

That is why, at LegaleGo, we approach international expansion of food supplements through three critical decision points:

Before formulation

Analysing multi-country ingredient viability, identifying regulatory red flags and classification risks.

Before expansion

Identifying differences between markets, regulatory inconsistencies and the need for adaptation or reformulation.

When a block appears

Defining a regulatory strategy capable of protecting the market and minimising consequences.

Because expanding across Europe is not about accumulating notifications in multiple countries.

It is about building a regulatory strategy capable of sustaining long-term growth.

The difference between processing and deciding

This is where the real difference appears.

At LegaleGo Regulatory, we do not understand regulation as a simple administrative process.

We do not simply register products.

We develop regulatory strategies.

That means analysing:

• regulatory criteria;
• administrative practice;
• regulatory risk;
• multi-country viability;
• medium-term consequences;
• and international expansion consistency.

Because in international expansion of food supplements, compliance is not always enough.

And in Europe, the difference between growth and blockage rarely depends only on the product itself.

It depends on the regulatory strategy behind the expansion.